Login to Your Account



Value-based pricing: A cure for biopharma's durable therapy problem?

By Jennifer Boggs
Managing Editor

Tuesday, March 21, 2017

BARCELONA, Spain – With drug pricing in the political crosshairs and the first gene therapies advancing toward the market, the health care sector will have to figure how to put a price tag on therapies that provide durable, curative responses.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription